Last reviewed · How we verify
GSK573719 + GW642444 62.5/25
GSK573719 + GW642444 62.5/25 is a Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment. Also known as: Low Dose Dual.
GSK573719 (umeclidinium) and GW642444 (vilanterol) work together as a long-acting anticholinergic and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
GSK573719 (umeclidinium) and GW642444 (vilanterol) work together as a long-acting anticholinergic and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | GSK573719 + GW642444 62.5/25 |
|---|---|
| Also known as | Low Dose Dual |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) |
| Target | M3 muscarinic receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
GSK573719 is a muscarinic M3 receptor antagonist that blocks acetylcholine-induced bronchoconstriction, while GW642444 is a beta-2 adrenergic agonist that stimulates bronchodilation. Together in this fixed-dose combination (marketed as Anoro Ellipta), they provide dual bronchodilation through complementary mechanisms, improving lung function and reducing exacerbations in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nasopharyngitis
Key clinical trials
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (PHASE3)
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses (PHASE1)
- 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK573719 + GW642444 62.5/25 CI brief — competitive landscape report
- GSK573719 + GW642444 62.5/25 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK573719 + GW642444 62.5/25
What is GSK573719 + GW642444 62.5/25?
How does GSK573719 + GW642444 62.5/25 work?
What is GSK573719 + GW642444 62.5/25 used for?
Who makes GSK573719 + GW642444 62.5/25?
Is GSK573719 + GW642444 62.5/25 also known as anything else?
What drug class is GSK573719 + GW642444 62.5/25 in?
What development phase is GSK573719 + GW642444 62.5/25 in?
What are the side effects of GSK573719 + GW642444 62.5/25?
What does GSK573719 + GW642444 62.5/25 target?
Related
- Drug class: All Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) drugs
- Target: All drugs targeting M3 muscarinic receptor; beta-2 adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Also known as: Low Dose Dual
- Compare: GSK573719 + GW642444 62.5/25 vs similar drugs
- Pricing: GSK573719 + GW642444 62.5/25 cost, discount & access